Home
Services
Financial Services
Banking
Investment Banking
Merger & Acquisition in General Medicine and Specialty Medicine, Q3 2010

Investment Banking

Summary

Table of Contents

Data Series

Merger & Acquisition in General Medicine and Specialty Medicine, Q3 2010

Publication date: October 2012
Report size: 97 pages

Keywords : venture capital, private equity, M&A deal, raise capital

Search ReportLinker

The Largest Collection of Market Research Reports

» 1.2 Million Industry Reports
» 450,000 Company Profiles

» 850,000 Market Briefings
» 40,000 Country Guides

From +200,000 authoritative sources

GlobalData's “Partnerships, Licensing, Investments and M&A Deals and Trends in Pharmaceuticals - Q3 2010” report is an essential source of data and trend analysis on partnerships, licensing, mergers and acquisitions (M&As) and financings in the pharmaceuticals industry. The report provides detailed information on partnership and licensing transactions, M&As, equity/debt offerings, private equity, and venture financing registered in the pharmaceuticals industry in Q3 2010. The report portrays detailed comparative data on the number of deals and their value in the last five quarters, subdivided by deal types, various therapy areas, and geographies. Additionally, the report provides information on the top financial advisory firms in the pharmaceuticals industry

This report is systematically updated by our analysts for each new purchase. This is to ensure that you get the latest information available on the company. The report will be updated and sent to you in no later than 2 business days.

SWOT Analysis report provides you a strategic analysis and detailed overview of the company’s businesses and operations.

In this report, our analysts reveal the company’s business strategy, strengths, weakness, opportunities and threats and detailed information such as :
- Key events associated with the company,
- Major products, services and brands of the company,
- Key competitors,
- Key executives, biographies and employment history,
- Personnel heading key departments and functions,
- Important locations and subsidiaries
- Financial analysis and ratios based on the annual financial statements published by the company including a 5 years history.
- Interim ratios for the last five interim periods

You get also in deepth information about operations to identify potential customers, partners and suppliers. business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Latest Company Developments:

Global Investment Banking Industry

1 Table of Contents 2
I. 1 List of Data tables 4
I. 2 List of Charts 6

II Deal Summary 8
II. 1 Pharmaceuticals & Healthcare, World Deals Analysis, Q3 2010 8
II. 2 Pharmaceuticals & Healthcare, Global, by Type, Number of Deals and Deal Value, Q3 2010 10
II. 3 Pharmaceuticals & Healthcare, Global, Top Deals, Q3 2010 11
II. 3.1 Reckitt Benckiser To Take Over SSL 11
II. 3.2 Carlyle Group Completes Acquisition Of NBTY 11
II. 3.3 Johnson & Johnson To Take Over Additional Stake In Crucell 11
II. 3.4 Covance Concludes a New Deal With Sanofi-Aventis 12
II. 3.5 Gilead Sciences Completes Private Placement Of Senior Notes For US$ 2,200 Mln 12

III Pharmaceuticals & Healthcare, Merger and Acquisition Deal Summary, by Type 13
III. 1 Pharmaceuticals & Healthcare, Global, Merger and Acquisition, Q3 2010 13
III. 1.1 Top Merger and Acquisition Deals in Q3 2010 14
III. 1.2 Pharmaceuticals & Healthcare, World M&A Deals, by Therapy Area, Q3 2009 - Q3 2010 15
III. 2 Pharmaceuticals & Healthcare, Global, Equity Offering Deals, Q3 2010 16
III. 2.1 Top Initial Public Offerings in Q3 2010 17
III. 2.2 Top Secondary Offerings in Q3 2010 17
III. 2.3 Top PIPE Deals in Q3 2010 17
III. 2.4 Pharmaceuticals & Healthcare, Global, IPO deals, Q4 2009 – Q3 2010 18
III. 2.5 Pharmaceuticals & Healthcare, Global, Equity Offering Deals, by Therapy Area, Q3 2009 – Q3 2010 19
III. 3 Pharmaceuticals & Healthcare, Global, Debt Offering Deals, Q3 2010 20
III. 3.1 Top Public Debt Offerings in Q3 2010 21
III. 3.2 Top Private Debt Placements in Q3 2010 21
III. 3.3 Pharmaceuticals & Healthcare, Global, Debt Offering Deals, by Therapy Area, Q3 2009 - Q3 2010 22
III. 4 Pharmaceuticals & Healthcare, Global, Venture Capital Deals, Q3 2010 23
III. 4.1 Top Venture Financing Deals in Q3 2010 24
III. 4.2 Pharmaceuticals & Healthcare, Global, Venture Capital Deals, by Stage of Financing, Q3 2010 25
III. 4.3 Pharmaceuticals & Healthcare, Global, Venture Capital, by Therapy Area, Q3 2009 - Q3 2010 26
III. 4.4 Pharmaceuticals & Healthcare, Global, Top Venture Financing Firms, Q4 2009 – Q3 2010 27
III. 4.5 Pharmaceuticals & Healthcare, Global, Top VC Backed Firms, Q3 2010 28
III. 5 Pharmaceuticals & Healthcare, World Private Equity Deals, Q3 2010 29
III. 5.1 Top Private Equity Deals in Q3 2010 30
III. 5.2 Pharmaceuticals & Healthcare, Global, Private Equity Deals, by Therapy Area, Q3 2009 - Q3 2010 31

IV Pharmaceuticals & Healthcare, Global, Partnership Deals, Q3 2010 32
IV. 1 Pharmaceuticals & Healthcare, Global, Partnership Deals, Q3 2010 32
IV. 2 Pharmaceuticals & Healthcare, Global, Partnership Deals, by Therapy Area, Q3 2009 - Q3 2010 33
IV. 3 Pharmaceuticals & Healthcare, Global, Partnership Deals, by Upfront & Milestone Payment and Deal Value (US$ m), Q3 2010 34
IV. 3.1 Pharmaceuticals & Healthcare, Global, Top Partnership Deals, by Deal Value, Q3 2010 35
IV. 3.2 Pharmaceuticals & Healthcare, Global, Top Partnership Deals, by Upfront Payment, Q3 2010 35
IV. 3.3 Pharmaceuticals & Healthcare, Global, Top Partnership Deals, by Milestone Payment, Q3 2010 36
IV. 4 Pharmaceuticals & Healthcare, Global, Partnership Deals, by Therapy Area, by Upfront & Milestone Payment and Deal Value (US$ m), Q3 2009 - Q3 2010 37
IV. 5 Pharmaceuticals & Healthcare, Global, Partnership Deals, by Phase, Number Of Deals and Deal Value (US$ m), Q3 2009 - Q3 2010 38
IV. 6 Pharmaceuticals & Healthcare, Global, Partnership Deals, by Phase, by Upfront & Milestone Payment and Deal Value (US$ m), Q3 2009 - Q3 2010 39

V Pharmaceuticals & Healthcare, Global, Licensing Agreements, Q3 2010 40
V. 1 Pharmaceuticals & Healthcare, Global, Licensing Agreements, Q3 2010 40
V. 2 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, Upfront & Milestone Payment and Deal Value (US$ m), Q3 2009 - Q3 2010 41
V. 2.1 Pharmaceuticals & Healthcare, Global, Top Licensing Agreements, by Deal Value, Q3 2010 42
V. 2.2 Pharmaceuticals & Healthcare, Global, Top Licensing Agreements, by Total Upfront Payment, Q3 2010 42
V. 2.3 Pharmaceuticals & Healthcare, Global, Top Licensing Agreements, by Total Milestone Payment, Q3 2010 43
V. 2.4 Pharmaceuticals & Healthcare, Global, Licensing Agreements with Equity Investment, Q3 2009 – Q3 2010 43
V. 3 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Therapy Area, Total Deal Value (US$ m), Q3 2009 - Q3 2010 44
V. 4 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Therapy Area, Upfront Payment Vs Milestone Payment (US$ m), Q3 2009 - Q3 2010 45
V. 5 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Phase, Total Deal Value (US$ m), Q3 2009 - Q3 2010 46
V. 6 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Phase, Upfront Payment Vs Milestone Payment (US$ m), Q3 2009 - Q3 2010 47

VI Deal Summary by Therapy Area 48
VI. 1 Pharmaceuticals & Healthcare, Oncology Deals, Q3 2010 48
VI. 1.1 Oncology – Deals of the Quarter 49
VI. 2 Pharmaceuticals & Healthcare, Central Nervous System Deals, Q3 2010 50
VI. 2.1 Central Nervous System – Deals of the Quarter 51
VI. 3 Pharmaceuticals & Healthcare, Infectious Disease Deals, Q3 2010 52
VI. 3.1 Infectious Disease – Deals of the Quarter 53
VI. 4 Pharmaceuticals & Healthcare, Immunology Deals, Q3 2010 54
VI. 4.1 Immunology – Deals of the Quarter 55
VI. 5 Pharmaceuticals & Healthcare, Cardiovascular Deals, Q3 2010 56
VI. 5.1 Cardiovascular – Deals of the Quarter 57
VI. 6 Pharmaceuticals & Healthcare, Metabolic Disorders Deals, Q3 2010 58
VI. 6.1 Metabolic Disorders – Deals of the Quarter 59
VI. 7 Pharmaceuticals & Healthcare, Musculoskeletal Deals, Q3 2010 60
VI. 7.1 Musculoskeletal – Deals of the Quarter 61
VI. 8 Pharmaceuticals & Healthcare, Respiratory Deals, Q3 2010 62
VI. 8.1 Respiratory – Deals of the Quarter 63
VI. 9 Pharmaceuticals & Healthcare, Gastrointestinal Deals, Q3 2010 64
VI. 9.1 Gastrointestinal – Deals of the Quarter 65
VI. 10 Pharmaceuticals & Healthcare, Dermatology Deals, Q3 2010 66
VI. 10.1 Dermatology – Deals of the Quarter 67

VII Deal Summary by Geography 68
VII. 1 Pharmaceuticals & Healthcare, North America Region Deals, Q3 2010 68
VII. 1.1 North America – Deals of the Quarter 69
VII. 2 Pharmaceuticals & Healthcare, Europe Region Deals, Q3 2010 70
VII. 2.1 Europe – Deals of the Quarter 71
VII. 3 Pharmaceuticals & Healthcare, Asia-Pacific Deals, Q3 2010 72
VII. 3.1 Asia-Pacific – Deals of the Quarter 73
VII. 4 Pharmaceuticals & Healthcare, Rest of the World Deals, Q3 2010 74
VII. 4.1 Rest of the World – Deals of the Quarter 75

VIII Pharmaceuticals & Healthcare, Top Advisors 76
VIII. 1 Pharmaceuticals & Healthcare, World Top Financial Advisors, Merger and Acquisition, Q4 2009 - Q3 2010 76
VIII. 2 Pharmaceuticals & Healthcare, Top Financial Advisors, Equity Offerings, Q4 2009 - Q3 2010 77

IX Further Information 78
IX. 1 Methodology 78
IX. 2 About GlobalData 78
IX. 3 Contact Us 79
IX. 4 Disclosure information 79
IX. 5 Disclaimer 79
1.1 List of Data tables
Data table 1: Pharmaceuticals & Healthcare, Global, Merger and Acquisition Deal Summary, Number of Deals and Deal Value (US$m), Q3 2009 - Q3 2010 9
Data table 2: Pharmaceuticals & Healthcare, Global, Number Of Deals and Deal Value (%), Q3 2010 10
Data table 3: Pharmaceuticals & Healthcare, Global, Top Deals, Q3 2010 11
Data table 4: Pharmaceuticals & Healthcare, Global, Merger and Acquisition, Merger and Acquisition Deal Summary, Number of Deals and Deal Value (US$ m), Q3 2009 – Q3 2010 13
Data table 5: Pharmaceuticals & Healthcare, Global, Top Merger and Acquisition Deals, Q3 2010 14
Data table 6: Pharmaceuticals & Healthcare, Global, Merger and Acquisition, Merger and Acquisition Deal Summary, Number of Deals and Deal Value (US$ m), by Therapy Area,, Q3 2009 - Q3 2010 15
Data table 7: Pharmaceuticals & Healthcare, Global, Equity Offerings, Merger and Acquisition Deal Summary, Number of Deals and Deal Value (US$m), Q3 2009 - Q3 2010 16
Data table 8: Pharmaceuticals & Healthcare, Global, Top Initial Public Offering Deals, Q3 2010 17
Data table 9: Pharmaceuticals & Healthcare, Global, Top Secondary Offering Deals, Q3 2010 17
Data table 10: Pharmaceuticals & Healthcare, Global, Top PIPE Deals, Q3 2010 17
Data table 11: Pharmaceuticals & Healthcare, Global, IPO Deals, Q4 2009 – Q3 2010 18
Data table 12: Pharmaceuticals & Healthcare, Global, Equity Offering Deals, Merger and Acquisition Deal Summary, Number of Deals and Deal Value (US$m),, Q3 2009 - Q3 2010 19
Data table 13: Pharmaceuticals & Healthcare, Global, Debt Offering, Merger and Acquisition Deal Summary, Number of Deals and Deal Value (US$ m), Q3 2009 - Q3 2010 20
Data table 14: Medical Equipment, Global, Top Public Debt Offerings, Q3 2010 21
Data table 15: Medical Equipment, Global, Top Private Debt Placements, Q3 2010 21
Data table 16: Pharmaceuticals & Healthcare, Global, Debt Offering Deals, Summary, Number of Deals and Deal Value (US$ m), Q3 2009 - Q3 2010 22
Data table 17: Pharmaceuticals & Healthcare, Global, Venture Capital, Merger and Acquisition Deal Summary, Number of Deals and Deal Value (US$ m), Q3 2009 - Q3 2010 23
Data table 18: Pharmaceuticals & Healthcare, Global, Top Venture Capital Deals, Q3 2010 24
Data table 19: Pharmaceuticals & Healthcare, Global, Venture Capital Deals, by Stage of Financing, Number Of Deals and Deal Value (%), Q3 2010 25
Data table 20: Pharmaceuticals & Healthcare, Global, Venture Capital Deals, by Therapy Area, Merger and Acquisition Deal Summary, Q3 2009 - Q3 2010 26
Data table 21: Pharmaceuticals & Healthcare, Global, Top Venture Financing Firms, Number of Deals and Deal Value (US$ m), Q3 2009 – Q3 2010 27
Data table 22: Pharmaceuticals and Healthcare, Global, Top VC Backed Firms, April il 2010 – September tember 2010 28
Data table 23: Pharmaceuticals & Healthcare, Global, Private Equity, Merger and Acquisition Deal Summary, Number of Deals and Deal Value (US$ m), Q3 2009 – Q3 2010 29
Data table 24: Pharmaceuticals & Healthcare, Global, Top Private Equity Deals, Q3 2010 30
Data table 25: Pharmaceuticals & Healthcare, Global, Private Equity Deals, by Therapy Area, Merger and Acquisition Deal Summary, Q3 2009 - Q3 2010 31
Data table 26: Pharmaceuticals & Healthcare, Global, Partnerships, Number of Deals and Deal Value (US$ m), Q3 2009 - Q3 2010 32
Data table 27: Pharmaceuticals & Healthcare, Global, Partnership Deals, by Therapy Area, Number of Deals and Deal Value (US$ m), Q3 2009 - Q3 2010 33
Data table 28: Pharmaceuticals & Healthcare, Partnership Deals, Upfront & Milestone Payment and Deal Value (US$ m), Q3 2009 - Q3 2010 34
Data table 29: Pharmaceuticals & Healthcare, Global, Partnerships, Upfront & Milestone Payment and Deal Value (US$ m), Q3 2010 35
Data table 30: Pharmaceuticals & Healthcare, Global, Top Partnership Deals, by Upfront Payment, Q3 2010 35
Data table 31: Pharmaceuticals & Healthcare, Global, Top Partnership Deals, by Milestone Payment, Q3 2010 36
Data table 32: Pharmaceuticals & Healthcare, Global, Partnership Deals, by Therapy Area, Upfront & Milestone Payment and Deal Value (US$ m), Q3 2009 - Q3 2010 37
Data table 33: Pharmaceuticals & Healthcare, Global, Partnership Deals, by Phase, Q3 2009 - Q3 2010 38
Data table 34: Pharmaceuticals & Healthcare, Global, Partnership Deals, by Upfront & Milestone Payment and Deal Value (US$ m), Q3 2009 - Q3 2010 39
Data table 35: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, Merger and Acquisition Deal Summary, Number of Deals and Deal Value (US$ m), Q3 2009 - Q3 2010 40
Data table 36: Pharmaceuticals & Healthcare, Global, Licensing Agreements, Merger and Acquisition Deal Summary, Upfront & Milestone Payment and Deal Value (US$ m), Q3 2009 - Q3 2010 41
Data table 37: Pharmaceuticals & Healthcare, Global, Top Licensing Agreement Deals, by Deal Value, Q3 2010 42
Data table 38: Pharmaceuticals & Healthcare, Global, Top Licensing Agreement Deals, by Total Upfront Payment, Q3 2010 42
Data table 39: Pharmaceuticals & Healthcare, Global, Top Licensing Agreement Deals, by Total Milestone Payment, Q3 2010 43
Data table 40: Pharmaceuticals & Healthcare, Global, Licensing Agreements with Equity Investment, Q3 2009 – Q3 2010 43
Data table 41: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Therapy Area, Number of Deals and Deal Value (US$ m), Q3 2009 - Q3 2010 44
Data table 42: Pharmaceuticals & Healthcare, Global, Licensing Agreements, by Therapy Area, by Upfront & Milestone Payment (US$ m), Q3 2009 - Q3 2010 45
Data table 43: Pharmaceuticals & Healthcare, Global, Partnership Deals, by Phase, Q3 2009 - Q3 2010 46
Data table 44: Pharmaceuticals & Healthcare, Global, Licensing Agreements, by Therapy Area, by Upfront & Milestone Payment and Deal Value (US$ m), Q3 2009 - Q3 2010 47
Data table 45: Pharmaceuticals & Healthcare, Global, Oncology, Merger and Acquisition Deal Summary, Number of Deals and Deal Value (US$ m), Q3 2009 - Q3 2010 49
Data table 46: Pharmaceuticals & Healthcare, Global, Central Nervous System, Merger and Acquisition Deal Summary, Number of Deals and Deal Value (US$ m), Q3 2009 - Q3 2010 51
Data table 47: Pharmaceuticals & Healthcare, Global, Infectious Disease, Merger and Acquisition Deal Summary, Number of Deals and Deal Value (US$ m), Q3 2009 - Q3 2010 53
Data table 48: Pharmaceuticals & Healthcare, Global, Immunology, Merger and Acquisition Deal Summary, Number of Deals and Deal Value (US$ m), Q3 2009 - Q3 2010 55
Data table 49: Pharmaceuticals & Healthcare, Global, Cardiovascular, Merger and Acquisition Deal Summary, Number of Deals and Deal Value (US$ m), Q3 2009 - Q3 2010 57
Data table 50: Pharmaceuticals & Healthcare, Global, Metabolic Disorders, Merger and Acquisition Deal Summary, Number of Deals and Deal Value (US$ m), Q3 2009 - Q3 2010 59
Data table 51: Pharmaceuticals & Healthcare, Global, Musculoskeletal, Merger and Acquisition Deal Summary, Number of Deals and Deal Value (US$ m), Q3 2009 - Q3 2010 61
Data table 52: Pharmaceuticals & Healthcare, Global, Respiratory, Merger and Acquisition Deal Summary, Number of Deals and Deal Value (US$ m), Q3 2009 - Q3 2010 63
Data table 53: Pharmaceuticals & Healthcare, Global, Gastrointestinal, Merger and Acquisition Deal Summary, Number of Deals and Deal Value (US$ m), Q3 2009 - Q3 2010 64
Data table 54: Pharmaceuticals & Healthcare, Global, Dermatology, Merger and Acquisition Deal Summary, Number of Deals and Deal Value (US$ m), Q3 2009 - Q3 2010 66
Data table 55: Pharmaceuticals & Healthcare, North America, Merger and Acquisition Deal Summary, Number of Deals and Deal Value (US$ m), Q3 2009 - Q3 2010 69
Data table 56: Pharmaceuticals & Healthcare, Europe, Merger and Acquisition Deal Summary, Number of Deals and Deal Value (US$ m), Q3 2009 - Q3 2010 71
Data table 57: Pharmaceuticals & Healthcare, Asia-Pacific, Merger and Acquisition Deal Summary, Number of Deals and Deal Value (US$ m), Q3 2009 - Q3 2010 73
Data table 58: Pharmaceuticals & Healthcare, Rest of the World, Merger and Acquisition Deal Summary, Number of Deals and Deal Value (US$ m), Q3 2009 - Q3 2010 74
Data table 59: Pharmaceuticals & Healthcare, Top Financial Advisors, Merger and Acquisition, Number of Deals and Deal Value (US$ m), Q4 2009 - Q3 2010 76
Data table 60: Pharmaceuticals & Healthcare, World Top Financial Advisors, Equity Offerings, Number of Deals and Deal Value (US$ m), Q3 2010 77
1.2 List of Charts
Chart 1: Pharmaceuticals & Healthcare, Global, Number of Deals and Deal Value (US$m), Q3 2009 - Q3 2010 8
Chart 2: Pharmaceuticals & Healthcare, Global, Number Of Deals (%) and Deal Value (%), Q3 2010 10
Chart 3: Pharmaceuticals & Healthcare, Global, Merger and Acquisition, Number of Deals and Deal Value (US$m), Q3 2009 - Q3 2010 13
Chart 4: Pharmaceuticals & Healthcare, Global, Merger and Acquisition, by Therapy Area, Number of Deals and Deal Value (US$m), by Therapy Area, Q3 2009 – Q3 2010 15
Chart 5: Pharmaceuticals & Healthcare, Global, Equity Offering Deals, Number of Deals and Deal Value (US$ m), Q3 2009 - Q3 2010 16
Chart 6: Pharmaceuticals & Healthcare, Global, Equity Offering Deals, by Therapy Area, Number of Deals and Deal Value (US$m),, Q3 2009 – Q3 2010 19
Chart 7: Pharmaceuticals & Healthcare, Global, Debt Offering Deals, Number of Deals and Deal Value (US$m), Q3 2009 - Q3 2010 20
Chart 8: Pharmaceuticals & Healthcare, Global, Debt Offering Deals, by Therapy Area, Number of Deals and Deal Value (US$ m),, Q3 2009 - Q3 2010 22
Chart 9: Pharmaceuticals & Healthcare, Global, Venture Capital, Number of Deals and Deal Value (US$ m), Q3 2009 - Q3 2010 23
Chart 10: Pharmaceuticals & Healthcare, Global, Venture Capital Deals, by Stage of Financing, Number Of Deals (%) and Deal Value (%), Q3 2010 25
Chart 11: Pharmaceuticals & Healthcare, Global, Venture Capital Deals, by Therapy Area, Number of Deals and Deal Value (US$ m), by Therapy Area, Q3 2009 - Q3 2010 26
Chart 12: Pharmaceuticals & Healthcare, Global, Top Venture Financing Firms, Number of Deals and Deal Value (US$ m), Q4 2009 – Q3 2010 27
Chart 13: Pharmaceuticals & Healthcare, Global, Private Equity, Number of Deals and Deal Value (US$ m), Q3 2009 – Q3 2010 29
Chart 14: Pharmaceuticals & Healthcare, Global, Private Equity Deals, by Therapy Area, Number of Deals and Deal Value (US$ m), by Therapy Area, Q3 2009 - Q3 2010 31
Chart 15: Pharmaceuticals & Healthcare, Global, Partnerships, Number of Deals and Deal Value (US$ m), Q3 2009 - Q3 2010 32
Chart 16: Pharmaceuticals & Healthcare, Global, Partnership Deals, by Therapy Area, Number of Deals and Deal Value (US$ m), Q3 2009 - Q3 2010 33
Chart 17: Pharmaceuticals & Healthcare, Global, Partnership Deals, Upfront & Milestone Payment and Deal Value (US$ m), Q3 2009 - Q3 2010 34
Chart 18: Pharmaceuticals & Healthcare, Global, Partnership Deals, by Therapy Area, Upfront & Milestone Payment and Deal Value (US$ m), Q3 2009 - Q3 2010 37
Chart 19: Pharmaceuticals & Healthcare, Global, Partnership Deals, by Phase, Q3 2009 - Q3 2010 38
Chart 20: Pharmaceuticals & Healthcare, Global, Partnership Deals, by Phase, by Upfront & Milestone Payment and Deal Value (US$ m), Q3 2009 - Q3 2010 39
Chart 21: Pharmaceuticals & Healthcare, Global, Licensing Agreements, Number of Deals and Deal Value (US$ m), Q3 2009 - Q3 2010 40
Chart 22: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Upfront & Milestone Payment and Deal Value (US$ m), Q3 2009 - Q3 2010 41
Chart 23: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Therapy Area, Number of Deals and Deal Value (US$ m), Q3 2009 - Q3 2010 44
Chart 24: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Therapy Area, Upfront & Milestone Payment and Deal Value (US$ m), Q3 2009 - Q3 2010 45
Chart 25: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Phase, Number Of Deals and Deal Value (US$ m), Q3 2009 - Q3 2010 46
Chart 26: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Phase, by Upfront & Milestone Payment and Deal Value (US$ m), Q3 2009 - Q3 2010 47
Chart 27: Pharmaceuticals & Healthcare, Global, Oncology, Number of Deals and Deal Value (US$ m), Q3 2009 - Q3 2010 48
Chart 28: Pharmaceuticals & Healthcare, Global, Central Nervous System, Number of Deals and Deal Value (US$ m), Q3 2009 - Q3 2010 50
Chart 29: Pharmaceuticals & Healthcare, Global, Infectious Disease, Number of Deals and Deal Value (US$ m), Q3 2009 - Q3 2010 52
Chart 30: Pharmaceuticals & Healthcare, Global, Immunology, Number of Deals and Deal Value (US$ m), Q3 2009 - Q3 2010 54
Chart 31: Pharmaceuticals & Healthcare, Global, Cardiovascular, Number of Deals and Deal Value (US$ m), Q3 2009 - Q3 2010 56
Chart 32: Pharmaceuticals & Healthcare, Global, Metabolic Disorders, Number of Deals and Deal Value (US$ m), Q3 2009 - Q3 2010 58
Chart 33: Pharmaceuticals & Healthcare, Global, Musculoskeletal, Merger and Acquisition Deal Summary, Number of Deals and Deal Value (US$ m), Q3 2009 - Q3 2010 60
Chart 34: Pharmaceuticals & Healthcare, Global, Respiratory, Merger and Acquisition Deal Summary, Number of Deals and Deal Value (US$ m), Q3 2009 - Q3 2010 62
Chart 35: Pharmaceuticals & Healthcare, Global, Gastrointestinal, Merger and Acquisition Deal Summary, Number of Deals and Deal Value (US$ m), Q3 2009 - Q3 2010 64
Chart 36: Pharmaceuticals & Healthcare, Global, Dermatology, Merger and Acquisition Deal Summary, Number of Deals and Deal Value (US$ m), Q3 2009 - Q3 2010 66
Chart 37: Pharmaceuticals & Healthcare, North America, Number of Deals and Deal Value (US$ m), Q3 2009 - Q3 2010 68
Chart 38: Pharmaceuticals & Healthcare, Europe, Number of Deals and Deal Value (US$ m), Q3 2009 - Q3 2010 70
Chart 39: Pharmaceuticals & Healthcare, Asia-Pacific, Number of Deals and Deal Value (US$ m), Q3 2009 - Q3 2010 72
Chart 40: Pharmaceuticals & Healthcare, Rest of the World, Number of Deals and Deal Value (US$ m), Q3 2009 - Q3 2010 74
Chart 41: Pharmaceuticals & Healthcare, Top Financial Advisors, Merger and Acquisition, Number of Deals and Deal Value (US$ m), Q3 2010 76
Chart 42: Pharmaceuticals & Healthcare, World Top Financial Advisors, Equity Offerings, Number of Deals and Deal Value (US$ m), Q4 2009 - Q3 2010 77

Companies mentioned

Talk to Alison

00 1 718 618 48 97

Send Your Request

Follow

Add to circles Subscribe to our RSS feeds!

Global Investment Banking Industry : Latest Reports

Merger and Acquisition Trends in the Global Automotive OEM Industry

$ 6 000
Industry report
April 2013
by Frost & Sullivan

M&As Gain Importance as Financing Options in the Automotive OEM Industry This research service analyzes merger and acquisition trends in the global automotive industry with respect to year, deal volume, ...

Global Backend-as-a-service Market 2012-2016

$ 2 000
Industry report
February 2013
by Infiniti Research Limited

TechNavio's analysts forecast the Global Backend-as-a-Service (BaaS) market to grow at a CAGR of 100.9 percent over the period 2012-2016. One of the key factors contributing to this market growth is the ...

Power Quarterly Deals Analysis: M&A and Investment Trends - Q4 2012

$ 1 500
Industry report
January 2013
by Global Data

Power Quarterly Deals Analysis: M&A and Investment Trends - Q4 2012 Summary GlobalData's ?Power Quarterly Deals Analysis: M&A and Investment Trends - Q4 2012? report is an essential source of data and ...

Partnerships, Licensing, Investments And M ...

January 2013 $ 1 500

Power Quarterly Deals Analysis: M&a And In ...

April 2013 $ 1 500

Partnerships, Licensing, Investments And M ...

April 2013 $ 1 500

Corporate Financing Week - Yearly Subscrip ...

April 2013 $ 1 088

Global Macro Monitor - All Regions Edition ...

April 2013 $ 1 088

Global Macro Monitor - Asia Edition - Year ...

April 2013 $ 1 088

Partnerships, Licensing, Investments And M ...

February 2013 $ 1 000

More Reports:

Investment Banking in Australia (26)

Investment Banking in China (31)

Investment Banking in France (32)

Investment Banking in Germany (23)

Investment Banking in India (24)

Investment Banking in Italy (20)

Investment ... in the United Kingdom (23)

Investment ... in the United States (129)

Company Reports

Biogen Idec

Hsbc Equipment Finance Ltd.

Hutchison Telephone Company Ltd.

Solucient L.L.C.

Appcelerator Inc.

Global Investment Banking Industry : Latest Downloads

Bond Market Business Analysis

Industry report
April 2013
56 pages

... For bonds to the right at the same time that the supply curve for bonds shifts to the right because of the deficit. If nothing else changes, an increase in government borrowing shifts the bond supply curve ...

World Investment Banking Industry

Industry report
April 2013
15 pages

... Target equity returns: 5-20% debt: 3-6%; actual returns n/a vc/pe equity target returns 10-20%+; actual returns: -51% to 106% corporate investment (indirect) project investment (direct) investment fund ...

Debt Market Business Brief

Industry report
March 2013
8 pages

... That the local corporates turned to the foreign currency debt market rather than the loan market to obtain funding. This might be a sign that the debt market had gained ground against the loan market ...

More Reports:

Investment Banking in Australia (22)

Investment Banking in Canada (23)

Investment Banking in China (35)

Investment Banking in India (70)

Country Reports

World

ReportLinker is a professional search engine that provides an easy access to 1,2 million market research reports and industry statistics published by 200,000 authoritative sources.